Skip to content

Study · Non-randomized trial · n = 25 · 2001

5 results

The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy.

The source lists no authors.

Ophthalmology1 Dec 2001Cited by 33 (Europe PMC)

PMID11733269 (opens in a new tab)DOI10.1016/s0161-6420(01)00853-3 (opens in a new tab)PepBankPUB-11733269
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with proliferative diabetic retinopathy, no patient showed retinopathy regression during pegvisomant treatment.

    In plain wordsIn patients with proliferative diabetic retinopathy, pegvisomant treatment produced no observed retinopathy regression.

    Peptide
    Pegvisomant
    Outcome
    No significant changeRetinopathy regression
    Study

    n = 25

    Comparator
    Baseline
    Outcome group
    Vision and retina · Eye
    Studied dose
    100 mg loading dose, then 20 mg daily · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Regression of retinopathy was not observed in any patient.
    3 context sentences
    Summary · context
    A prospective, single-group, open-label, phase IIa multicenter trial was conducted.
    Summary · context
    Twenty-five patients with diabetes mellitus (13 with type 1 and 12 with type 2) and proliferative diabetic retinopathy aged 21 years or older were enrolled.
    Summary · context
    Patients received an initial loading dose of 100 mg pegvisomant by subcutaneous injection, followed by self-administered injections of 20 mg daily for 12 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    After pegvisomant, neovascularization remained unchanged in 16 patients (9/13 type 1, 7/12 type 2) and progressed in 9 (4/13 type 1, 5/12 type 2).

    In plain wordsIn patients with diabetic retinopathy, neovascularization remained unchanged in 16 and progressed in 9 after pegvisomant treatment.

    Peptide
    Pegvisomant
    Outcome
    MixedRetinal neovascularization status
    Study

    n = 25

    Comparator
    Baseline
    Outcome group
    Vision and retina · Eye
    Studied dose
    100 mg loading dose, then 20 mg daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Patients with unchanged neovascularization
    16 patients
    all patients, end of treatment (of 25)
    Patients with unchanged neovascularization
    9 patients
    type 1 diabetes (of 13)
    Patients with unchanged neovascularization
    7 patients
    type 2 diabetes (of 12)
    Patients with progressed neovascularization
    9 patients
    all patients, end of treatment (of 25)
    Patients with progressed neovascularization
    4 patients
    type 1 diabetes (of 13)
    Patients with progressed neovascularization
    5 patients
    type 2 diabetes (of 12)

    Source sentences

    Summary
    At the end of the treatment period, the extent of neovascularization in the study eye was unchanged in 16 patients (9 of 13 with type 1 and 7 of 12 with type 2) and had progressed in 9 patients (4 of 13 with type 1 and 5 of 12 with type 2).
    3 context sentences
    Summary · context
    A prospective, single-group, open-label, phase IIa multicenter trial was conducted.
    Summary · context
    Twenty-five patients with diabetes mellitus (13 with type 1 and 12 with type 2) and proliferative diabetic retinopathy aged 21 years or older were enrolled.
    Summary · context
    Patients received an initial loading dose of 100 mg pegvisomant by subcutaneous injection, followed by self-administered injections of 20 mg daily for 12 weeks.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with proliferative diabetic retinopathy, maximum IGF-I reduction from baseline averaged 55% per patient during pegvisomant treatment.

    In plain wordsIn patients with diabetic retinopathy, pegvisomant treatment reduced IGF-I from baseline.

    Peptide
    Pegvisomant
    Outcome
    DecreaseMaximum serum IGF-I reduction
    Study

    n = 25

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 mg loading dose, then 20 mg daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Maximum reduction from baseline in serum IGF-I per patient
    55 percent
    average across patients

    Source sentences

    Summary
    The maximum reduction from baseline per patient in the insulin-like growth factor-I (IGF-I) serum level averaged 55%; 17 (68%) of the 25 patients had a greater than 50% reduction in IGF-I.
    3 context sentences
    Summary · context
    A prospective, single-group, open-label, phase IIa multicenter trial was conducted.
    Summary · context
    Twenty-five patients with diabetes mellitus (13 with type 1 and 12 with type 2) and proliferative diabetic retinopathy aged 21 years or older were enrolled.
    Summary · context
    Patients received an initial loading dose of 100 mg pegvisomant by subcutaneous injection, followed by self-administered injections of 20 mg daily for 12 weeks.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with proliferative diabetic retinopathy, 17 of 25 (68%) had an IGF-I reduction greater than 50% with pegvisomant.

    In plain wordsIn patients with diabetic retinopathy, 68% had an IGF-I reduction greater than 50% with pegvisomant.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGF-I reduction exceeding 50%
    Study

    n = 25

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 mg loading dose, then 20 mg daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Patients with IGF-I reduction greater than 50%
    17 patients
    of 25 patients
    Patients with IGF-I reduction greater than 50%
    68 percent
    of 25 patients

    Source sentences

    Summary
    The maximum reduction from baseline per patient in the insulin-like growth factor-I (IGF-I) serum level averaged 55%; 17 (68%) of the 25 patients had a greater than 50% reduction in IGF-I.
    3 context sentences
    Summary · context
    A prospective, single-group, open-label, phase IIa multicenter trial was conducted.
    Summary · context
    Twenty-five patients with diabetes mellitus (13 with type 1 and 12 with type 2) and proliferative diabetic retinopathy aged 21 years or older were enrolled.
    Summary · context
    Patients received an initial loading dose of 100 mg pegvisomant by subcutaneous injection, followed by self-administered injections of 20 mg daily for 12 weeks.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with proliferative diabetic retinopathy, IGF-I returned to baseline after pegvisomant discontinuation.

    In plain wordsIn patients with diabetic retinopathy, IGF-I returned to baseline after pegvisomant discontinuation.

    Peptide
    Pegvisomant
    Outcome
    No significant changeIGF-I after discontinuation
    Study

    n = 25

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 mg loading dose, then 20 mg daily · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After treatment was discontinued, IGF-I levels returned to baseline.
    3 context sentences
    Summary · context
    A prospective, single-group, open-label, phase IIa multicenter trial was conducted.
    Summary · context
    Twenty-five patients with diabetes mellitus (13 with type 1 and 12 with type 2) and proliferative diabetic retinopathy aged 21 years or older were enrolled.
    Summary · context
    Patients received an initial loading dose of 100 mg pegvisomant by subcutaneous injection, followed by self-administered injections of 20 mg daily for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.